- Home
- MRCC vs IPSC Comparison
MRCC vs IPSC Comparison
Compare MRCC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- IPSC
- Stock Information
- Founded
- MRCC 2011
- IPSC 2019
- Country
- MRCC United States
- IPSC United States
- Employees
- MRCC N/A
- IPSC N/A
- Industry
- MRCC Investment Managers
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- MRCC Finance
- IPSC Health Care
- Exchange
- MRCC Nasdaq
- IPSC Nasdaq
- Market Cap
- MRCC 174.8M
- IPSC 146.2M
- IPO Year
- MRCC 2012
- IPSC 2021
- Fundamental
- Price
- MRCC $8.21
- IPSC $1.17
- Analyst Decision
- MRCC Strong Buy
- IPSC Strong Buy
- Analyst Count
- MRCC 1
- IPSC 4
- Target Price
- MRCC $9.00
- IPSC $13.00
- AVG Volume (30 Days)
- MRCC 71.5K
- IPSC 764.5K
- Earning Date
- MRCC 11-12-2024
- IPSC 11-05-2024
- Dividend Yield
- MRCC 12.15%
- IPSC N/A
- EPS Growth
- MRCC 298.01
- IPSC N/A
- EPS
- MRCC 0.60
- IPSC N/A
- Revenue
- MRCC $62,007,000.00
- IPSC $2,684,000.00
- Revenue This Year
- MRCC N/A
- IPSC $230.56
- Revenue Next Year
- MRCC N/A
- IPSC $31.85
- P/E Ratio
- MRCC $13.71
- IPSC N/A
- Revenue Growth
- MRCC N/A
- IPSC 7.88
- 52 Week Low
- MRCC $6.77
- IPSC $1.13
- 52 Week High
- MRCC $8.74
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- MRCC 42.18
- IPSC 37.46
- Support Level
- MRCC $8.37
- IPSC $1.40
- Resistance Level
- MRCC $8.66
- IPSC $1.74
- Average True Range (ATR)
- MRCC 0.19
- IPSC 0.16
- MACD
- MRCC -0.05
- IPSC -0.03
- Stochastic Oscillator
- MRCC 1.85
- IPSC 5.71
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.